UroGen Pharma (URGN) Operating Income (2017 - 2026)

UroGen Pharma (URGN) has reported Operating Income for 10 consecutive years, with -$20.3 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Income rose 45.11% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.2 million (changed 0.24% YoY) and the FY2025 annual result came in at -$124.9 million, down 29.01% from the prior year.
• Operating Income eased to -$20.3 million in Q1 2026 per URGN's latest filing, from -$19.1 million in the prior quarter.
• Over the last five years, Operating Income for URGN reached as high as -$13.5 million in Q3 2023 and fell as low as -$41.4 million in Q2 2025.
• A 5-year average of -$22.7 million and a median of -$20.3 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2024 — Operating Income sank 89.32% — and 2026, when it soared 45.11%.
• Year by year, Operating Income stood at -$20.3 million in 2022, then gained by 27.97% to -$14.6 million in 2023, then tumbled by 89.32% to -$27.7 million in 2024, then surged by 30.89% to -$19.1 million in 2025, then decreased by 6.01% to -$20.3 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$20.3 million, -$19.1 million, and -$27.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.